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ABSTRACT
Metastasis is the final stage of cancer progression. Some evidence indicates that 
tumor cell dissemination occurs early in the natural history of cancer progression. 
Disseminated tumor cells (DTC) have been described in the bone marrow (BM) of 
cancer patients as well as in experimental models, where they correlate with later 
development of metastasis. However, little is known about the tumorigenic features 
of DTC obtained at different time points along tumor progression. Here, we found 
that early DTC isolated from BM of 15-17 week-old Her2/neu transgenic (BALB-neuT) 
mice were not tumorigenic in immunodeficient mice. In contrast, DTC-derived tumors 
were easily detectable when late DTC obtained from 19-22 week-old BALB-neuT 
mice were injected. Angiogenesis, which contributes to regulate tumor dormancy, 
appeared dispensable to reactivate late DTC, although it accelerated growth of 
secondary DTC tumors. Compared with parental mammary tumors, gene expression 
profiling disclosed a distinctive transcriptional signature of late DTC tumors which was 
enriched for hypoxia-related transcripts and was maintained in ex-vivo cell culture. 
Altogether, these findings highlight a different tumorigenic potential of early and late 
DTC in the BALB-neuT model and describe a HIF-1α-related transcriptional signature 
in DTC tumors, which may render DTC angiogenesis-competent, when placed in a 
favourable environment.
INTRODUCTION
Despite advances in early detection of cancer, 
metastasis still constitutes a major obstacle in treating 
cancer patients, due to poor understanding of key factors 
regulating its occurrence [1, 2]. The prevailing view 
assumes that tumor cells can acquire ability to metastasize 
in advanced cancer stages [3], but this contrasts with 
the finding that some early-stage cancer patients already 
present solitary tumor cells in the bone marrow (BM) 
[1]. Moreover, the emergence of metastasis years or even 
decades after apparently successful surgical removal and 
treatment of primary lesions argues for the reactivation 
of residual disseminated tumor cells (DTC) [1, 4, 5]. To 
explain this phenomenon, it has been proposed that after 
conventional cancer treatments some tumor cells may 
survive in a state of dormancy lodged in different organs, 
whereby they are not clinically detected [4]. Thereafter, 
by as yet unknown mechanisms, these cells switch to 
a proliferative state and produce a relapse [4, 5]. The 
identification of factors that regulate tumor dormancy 
may thus provide new insights for preventing the arising 
of metastasis.
The presence of DTC in the BM of breast cancer 
patients has been found to be a strong predictor for local 
relapse, metastasis and overall survival [6]. A similar 
correlation has been described even in colo-rectal cancer 
patients, who rarely develop skeletal metastasis [7]. 
Further characterization of DTC has revealed that most 
cells obtained from carcinoma patients are viable and their 
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proliferative capacity is associated with worst prognosis 
[8]. In contrast, other studies have shown that DTC are 
heterogeneous, with some displaying fewer chromosomal 
aberrations compared to the primary tumor counterpart, 
suggesting that their inability to colonize distant organs 
is due to their non-fully transformed status [9-11]. Some 
studies also claimed that most DTC found in the BM 
exhibit stem cell features [12], while others have proposed 
that DTC dormancy could result from the balance of 
surrounding mitogenic and stress signals [13]. Which 
pre-existing feature or condition endows tumorigenic/
metastatic capacity to DTC is still unknown, although it 
is likely that a combination of both intrinsic (genetic and/
or epigenetic) and microenvironmental factors could be at 
play. Therefore, whilst DTC detection has been accepted 
as an independent prognostic tool in the clinics, their 
role in tumor recurrence and metastasis, as well as the 
underlying mechanisms, is far from clear.
In 2008, Hüsemann et al. demonstrated that DTC 
derived early during tumor progression (early DTC) were 
tumorigenic [14]. Using the BALB-neuT mouse mammary 
cancer model, these authors were able to accurately trace 
the timing of tumor cell dissemination at the earliest 
signs of atypical ductal hyperplasia in mammary glands 
of these animals [14]. An important finding of this study 
was that DTC from the BM of BALB-neuT mice could 
be reactivated when transplanted into irradiated syngeneic 
hosts. This suggested that DTC found in the BM have 
tumorigenic potential and lay dormant till they are released 
from this state by as yet unknown events. In this scenario, 
irradiation has been proposed to promote metastatic 
growth by inducing inflammation and angiogenesis [14-
16]. In previous studies, we and others have shown that 
angiogenesis can lead to escape from tumor dormancy in 
tumor xenograft models [17, 18]. Given these premises, 
we sought to further investigate the contribution of 
angiogenesis in the reactivation of DTC obtained at 
various stages of tumor progression in the BALB-neuT 
mouse mammary cancer model and to better characterize 
DTC-derived tumors.
RESULTS
Bone marrow-derived late, but not early, DTC 
have tumorigenic features
In the BALB-neuT transgenic mouse model, 
mammary cancer growth is driven by the activated 
rat Her2/neu oncogene under the hormone-responsive 
mouse mammary tumor virus promoter (MMTV) [19]. 
Identification of DTC in the BM of BALB-neuT mice 
relies on the detection by immunofluorescence of cells 
expressing either the epithelial cell marker CK8-18 or the 
Her2/neu oncogene (HER2) or both markers [14] (Figure 
1A). To test the tumorigenicity of DTC derived from the 
BM of BALB-neuT mice, 5 x 106 BM-derived cells were 
injected sub-cutaneously (s.c.) into immunodeficient 
female NOD-SCID-γ-/- (NSG) mice. Eleven-to-seventeen 
week-old BALB-neuT mice bearing pre-invasive lesions 
(including atypical hyperplasia and in situ carcinoma), 
were arbitrarily categorized as ‘early DTC donors’ (young 
BALB-neuT), whereas 19-to-22 week-old BALB-neuT 
mice bearing invasive carcinomas were classified as ‘late 
DTC donors’ (old BALB-neuT). As summarized in Table 
1, we did not observe any tumor in mice inoculated with 
early DTC (0/38 injection sites) over an eight-month 
observation period. On the contrary, injection of 16 out 
of 36 (44%) late DTC-containing BM cells gave rise to 
tumors (DTC tumors) (Table 1). No obvious correlation 
was seen between the estimated number of DTC present 
in the inocula and tumor generation (Table 1). Moreover 
we did not find statistically significant differences between 
late and early DTC in the expression of the CK8-18 and/
or HER2 markers (Table 1). In these experiments, we 
initially inoculated pools of BALB-neuT BM cells. 
Indeed, we observed a great variability in the timing of 
tumor development (Figure 1B), but donor variability 
in late DTC content did not apparently affect DTC 
tumorigenicity (Table 1). We therefore decided to use 
single DTC donor mice, bearing different tumor burden, 
and sought a correlation between tumor outgrowth, DTC 
contents, and time for tumor development. As shown in 
Supplementary Table S1, when BM cells from individual 
mice were used, we did not find any correlation between 
tumor burden (defined by total tumor volume and number 
of tumors) and DTC content, DTC phenotype or the 
tumorigenic behaviour of DTC in recipient mice.
Late DTC tumors recapitulate parental BALB/
neuT mammary tumors
DTC tumors expressed HER2 similarly to parental 
BALB-neuT mammary tumors (parental mammary 
tumor) and to BALB-neuT mammary tumor cells grown 
s.c. in NSG mice (mammary tumor; Figure 1C). Flow 
cytometry analysis confirmed these data and showed that 
HER2 expression in cells recovered from the DTC tumor 
was of similar intensity to the parental mammary tumor 
cells and TUBO cells, a cell line derived from a BALB-
neuT tumor (Supplementary Figure S1A). Moreover, 
cells recovered from DTC tumors could re-generate new 
tumors in immunodeficient as well as immunocompetent 
syngeneic mice (Table 2). To test whether angiogenic 
factors could positively affect DTC outgrowth, we 
initially tested the ability of two major angiogenic factors, 
bFGF and VEGF (vascular endothelial growth factor), 
in promoting blood vessel formation in our setting. BM-
derived cells were s.c. injected in Matrigel sponges with 
or without the angiogenic factor bFGF, VEGF alone or 
the combination of the two. As shown in Supplementary 
Figure S2A, only in the case of BM-derived cells injected 
with the bFGF or a combination of bFGF/VEGF we 
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could clearly observe blood vessel formation. Moreover, 
these angiogenic factors, alone or in combination, did not 
change the frequency of tumor development following 
injection of DTC-containing BM samples, as shown in 
Supplementary Figure S2B. We therefore set out a new 
experiment to determine whether bFGF could accelerate 
the outgrowth of late DTC. Thus BM-derived cells were 
injected s.c. into Matrigel supplemented with bFGF. After 
a 30-week observation period, comparable frequencies of 
tumors were observed in BM-derived cells containing late 
DTC injected with or without bFGF (Supplementary Table 
S2), suggesting that exogenous angiogenic factors are not 
needed to reactivate late DTC. In any case, bFGF was 
able to accelerate the growth of secondary DTC tumors 
(Supplementary Figure S1B). The same experiment was 
also performed by injecting early DTC in the presence or 
absence of bFGF; however, the presence of this angiogenic 
factor did not modify the tumorigenicity of early DTC and 
no tumor outgrowth was observed (data not shown).
Gene expression profiling identifies HIF-1α 
pathway deregulation in DTC tumors
To further characterize DTC tumorigenic behavior, 
we next compared gene expression profiles in DTC tumors 
and mammary tumors grown in the s.c. tissue of NSG 
mice (see Figure 1C). We analyzed genes differentially 
regulated in four DTC tumors and four mammary tumors. 
As shown in Figure 2A, bioinformatics and microarray 
analysis of mRNA expression profile revealed 26 top 
genes differentially regulated between DTC and mammary 
tumors. These include several relevant genes involved 
in the growth, proliferation and survival of cancer cells 
(Table 3). Furthermore, Ingenuity pathway analysis 
(IPA) identified relevant signalling networks activated 
and up-regulated in DTC tumors compared to mammary 
tumors (Figure 2B). Despite comparable tumor volume 
size (data not shown), DTC tumors showed increased 
levels of hypoxia-regulated genes such as the cytokine 
VEGF [20], Adm (adrenomedullin) [21], Bnip3 (BCL2/
Adenovirus E1B 19kD-Interacting Protein 3) [22], Pfkfb3 
(6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) 
[23], Itga9 (Integrin alpha-9) [24], and NRG1 (neuregulin 
1) [25] (Figure 2B). The mRNA expression of VEGF and 
BNIP3 was also validated by qPCR. As shown in Figure 
2C, DTC tumors expressed significantly more VEGF, 
compared to mammary tumors; however, this finding did 
not translate into differences in microvessel density (MVD) 
between the two types of tumors (data not shown). BNIP3 
expression also was up-regulated in DTC tumors compared 
to mammary tumors (Figure 2D) as well as the hypoxia-
regulated miRNA, miR-210 [26] (Figure 2E). Since VEGF 
and BNIP3 contain HIF-1α responsive elements (HRE), 
we inferred that DTC tumors could be more hypoxic. In 
fact, DTC tumors had larger necrotic areas compared to 
mammary tumors (Figure 2F). Furthermore, a significantly 
higher HIF-1α nuclear accumulation was seen in DTC 
tumors (Figure 2G). Altogether, these observations suggest 
that DTC tumors exhibit a relatively higher hypoxic 
phenotype than mammary tumors.
Figure 1: Tumorigenic capacities of BALB-neuT Disseminated Tumor Cells (DTC). A. Representative images of BM cells 
from BALB-neuT mice stained for Her2/neu oncogene (HER2) and Cytokeratin 8-18 (CK 8-18). CK8-18 positive cells are shown in 
green, HER2-positive cells in red and HER2/CK8-18 double-positive cells in yellow; nuclei are stained in blue. In the merge panel: 1, 
HER2-positive cells; 2, CK8-18 positive cell; 3, HER2/CK8-18 double-positive cell. Scale Bar, 20 μm. B. Growth curves of DTC tumors 
generated from the injection of late DTC from BALB-neuT BM pools. Tumor volumes were plotted as a function of time (weeks) after 
injection. C. Immunohistochemical analysis of HER2 expression in parental mammary tumor and tumors generated from the s.c. injection 
into NSG mice of BALB-neuT parental mammary tumor cells (mammary tumor, upper panels) and BALB-neuT BM cells (DTC tumor, 
lower panels). Light microscopy images were taken at 10x magnification (scale bar 200 μm) and 40x (scale bar 50 μm).
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Cells derived from DTC tumors maintain their 
hypoxic phenotype upon in vitro passage
To discern whether this hypoxic signature was 
imposed by the microenvironment or it was dependent 
on intrinsic features of tumor cells, we next investigated 
HIF-1α levels in the cells isolated from DTC tumors. 
After short in vitro expansion (2 to 4 passages) of the 
cells derived from a DTC tumor (DTC tumor cell line) 
and mammary tumor (Mammary tumor cell line) we 
evaluated protein levels of HIF-1α by Western blotting. 
Under normoxic culture conditions, we found almost 
four times more HIF-1α protein levels in the DTC-tumor 
cell line compared to the mammary tumor cell line, in 
which HIF-1α was barely detectable (Figure 3A-3B). As 
expected, HIF-1α accumulated in response to hypoxia in 
Table 1: Tumorigenic capability of early and late Disseminated Tumor Cells (DTC) in NSG micea
Donor Age
DTC 
injected 
HER2+
DTC 
injected 
CK8-18+
DTC 
injected 
HER2/CK8-
18+
Total no. 
of DTC 
injectedb
Tumors/
injected sites
Tumor take 
(%)
Early DTC 
donor
15 weeks 10 0 5 15 0/4
15 weeks 17 3 0 20 0/4
15 weeks 25 5 0 30 0/4
15 weeks 20 0 20 40 0/2
15 weeks 15 15 25 55 0/2
15 weeks 35 15 20 70 0/2
15 weeks 45 20 30 95 0/2
17.5 weeks n.d n.d n.d n.d 0/9
17.5 weeks n.d n.d n.d n.d 0/9
Total 0/38 0
Late DTC 
donor
20 weeks 3 6 3 12-15 4/12
20 weeks 5 14 2 21-22 1/8
20 weeks 20 0 5 20-30 3/6
20 weeks 30 0 6 30-40 6/8
19 weeks 15 35 0 50 2/2
Total 16/36 44
a) BM pools from BALB-neuT mice of various ages were harvested, and inoculated into the s.c. pocket of NSG mice (5 x 
106 BM-derived cells/site). Mice were inspected weekly and tumors scored when volume exceeded 10 mm3.
b) DTC number was estimated by staining for CK8-18 and HER2 antigens.
Table 2: DTC tumors can be serially transplanted into both immunodeficient and immunocompetent syngeneic micea
NSG mice BALB/c mice
Tumors/site 
inoculated
Tumor take (%) Tumors/site 
inoculated
Tumor take (%)
DTC Tumor cell line 1 12/12 100% 7/8 96.8%
DTC Tumor cell line 2 4/4 100% 8/8 100%
DTC Tumor cell line 3 4/4 100% 8/8 100%
Mammary Tumor cell line 4/4 100% 8/8 100%
a) Cells derived from DTC (DTC tumor cell line) or mammary tumors (mammary tumor cell line) were s.c. inoculated into 
immunodeficient NSG or immunocompetent syngeneic BALB/c mice. Mice were inspected weekly and tumors scored 
when volume exceeded 10 mm3.
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Figure 2: DTC tumors display enhanced expression of hypoxia-regulated genes. A. Heat map of differentially regulated 
genes; the green color depicts genes that are downregulated and the red denotes genes that are up-regulated in DTC tumors (DTC 1-4) and 
mammary tumors (T 1-4). B. Ingenuity pathway analysis (IPA) illustrating HIF-1α as a possible master regulator of differentially regulated 
genes in DTC tumors compared to mammary tumors. Up-regulated and down-regulated genes are shown in red and in green, respectively. 
C-D-E. VEGF C. and BNIP3 D. mRNA expression and miR-210 quantification E. in mammary and DTC tumors. The histograms depict 
relative expression compared to mammary tumor expressed as fold change. Data are expressed as mean values (± SD) of 4 different samples/
group. F. Histopathologic evaluation of necrotic areas in mammary and DTC tumors. Representative haematoxylin and eosin-stained 
sections (H&E) of each tumor type were photographed on the left at 10x (scale bar 200 μm). The right histogram illustrates the quantification 
of necrotic areas over total tumor area. Data are expressed as mean values (± SD) of 6 different samples/group. G. Immunohistochemical 
analysis of HIF-1α expression in frozen sections of mammary and DTC tumors. A representative image of each tumor stained for HIF-
1α is shown on the left at 20x; the quadrant indicates the area photographed at 40x (scale bar 100 μm). The right histogram shows the 
quantification of HIF-1α positive nuclei; data are expressed as mean values (± SD) of 5 different samples/group.*P < 0.05, **P < 0.01.
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both cell types (Figure 3A-3B). The cells maintained this 
phenotype for several in vitro passages (data not shown). 
We also evaluated the intra-cellular distribution of HIF-
1α by immunofluorescence in normoxia and hypoxia 
(Figure 3C). Whilst both cell lines in response to hypoxia 
showed nuclear localization of HIF-1α, we found also 
an intense cytoplasmic HIF-1α signal in DTC tumor 
cell line in normoxia (Figure 3C). In contrast, HIF-1α 
was barely detectable in the cultures from the mammary 
tumor cell line (Figure 3C). We next examined whether 
gene expression levels of VEGF and BNIP3 transcripts 
were affected. As shown in Figure 3D, VEGF mRNA 
levels of the DTC tumor cells almost doubled compared 
to mammary tumor cells. The mRNA levels of BNIP3 
also were markedly up-regulated in DTC compared to 
mammary tumor cell line (Figure 3E). In support to these 
results, also miR-210 was considerably up-regulated in 
the DTC tumor cell line (Figure 3F). As expected, these 
transcripts were strongly upregulated in each cell line 
following exposure to hypoxia (Figure 3G and 3H). 
Altogether, these findings indicated that cells derived from 
DTC tumors stably maintain in vitro a hypoxic phenotype.
Table 3: Top differentially regulated genes between mammary tumors and DTC tumorsa
Gene Symbol log2 Fold Change mammary vs. DTC tumor P Value
Tfap2b 4.00 0.00004
Abpb 2.66 0.02277
Mfi2 1.72 0.01500
Arhgef6 1.62 0.03335
Igfals 1.54 0.01500
S100b 1.27 0.03968
Crabp2 1.27 0.02177
Nes 1.26 0.01500
Cpeb2 1.18 0.04957
C630004H02Rik 1.07 0.02490
Cgrrf1 1.06 0.03335
Clybl 1.04 0.04957
Slc44a3 1.02 0.03936
Vegfa -1.03 0.04872
Itga9 -1.21 0.03968
Il2rg -1.24 0.02322
Ppp1r9a -1.36 0.01500
Pfkfb3 -1.42 0.01808
Bnip3 -1.87 0.03936
Eps8 -1.95 0.01808
Adm -2.00 0.01808
Ndrg1 -2.28 0.01500
Tspan8 -2.30 0.04836
2610528A11Rik -2.51 0.04746
Dcpp1 -3.93 0.01500
Dcpp2 -4.59 0.02490
a) RNA from DTC tumors and mammary tumors where used to hybridize Affymetrix chips. Top differentially expressed 
genes were calculated using cut-off of 0.05 P value with the Bonferroni correction method. The table lists differentially 
expressed genes (gene symbols), their magnitude expressed as fold change of mammary vs. DTC tumor expression level 
(Log2 Fold Change) and the False Discovery Rate (FDR) P-value score.
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HIF-1α is required for DTC tumorigenic 
potential
To determine whether this hypoxic signature was 
necessary for DTC tumor growth, we silenced HIF-1α in 
DTC by lentiviral vectors expressing HIF-1α-specific short 
hairpin (sh) RNA and monitored their growth in the s.c. 
pocket of NSG mice (Figure 4A-4E). Notwithstanding a 
modest (20-30%) reduction in the mRNA levels of HIF-1α 
and its downstream target genes VEGF and BNIP3 (Figure 
4A), we observed significant differences in tumor growth 
between silenced DTC and control cells (Figure 4B). As 
shown in Figure 4C, HIF-1α-silenced DTC cells (shHIF-
1α) formed smaller tumors compared to control (shRNA) 
cells. The recovered tumors were morphologically similar 
to controls, as shown by H&E staining (Figure 4D) and 
maintained downregulated expression of HIF-1α and its 
two target genes VEGF and BNIP3 (Figure 4E).
Since we previously observed differences in early 
and late DTC tumorigenicity we evaluated HIF-1α 
expression in BM samples containing early or late DTC. 
As shown in Figure 4F, the BM of late DTC donors 
contained a significantly higher number of CK8-18+/HIF-
1α+ DTC. Altogether, these results suggest that HIF-1α 
plays a role in the outgrowth of DTC tumors.
Figure 3: DTC tumor cells maintain in vitro up-regulation of HIF-1α expression. A. Western blot analysis of HIF-1α protein 
levels in mammary and DTC tumor cell lines cultured under normoxic (N) or hypoxic (H) conditions. The molecular weight of HIF-1α and 
Actin, used as a loading control is indicated on the right. B. Quantification of HIF-1α protein expression by densitometry. The histograms 
represent quantification of HIF-1α normalized to individual actin levels, and relative to HIF-1α protein levels in normoxia of mammary 
tumor cell line. C. Immunofluorescence analysis of HIF-1α localization in mammary and DTC tumor cell lines in normoxic (top row) and 
hypoxic conditions (bottom row). In green HIF-1α staining, in blue nuclei. Images acquired at 40x and 63x magnification, scale bar 10 μm. 
D-E-F. qPCR analysis of VEGF D. and BNIP3 E. mRNA levels and miR-210 expression F. in cells derived from mammary and DTC tumor 
cell lines. G-H. qPCR analysis of VEGF, BNIP3 and miR-210 levels following incubation under hypoxia in mammary G. and DTC tumor 
cell lines H. Data are presented as relative to level under normoxic conditions. All data represent mean values ± SD. *P < 0.05, **P < 0.01.
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DTC tumors and metastasis tumors partly share 
the hypoxic phenotype
To compare the phenotype of DTC tumors and 
BALB-neuT lung metastasis, we generated s.c. tumors by 
injecting NSG mice with metastatic cells dissociated from 
the lungs of 28-week-old BALB-neuT mice, according to 
the experimental layout shown in Figure 5A. As shown 
in Figure 5A (top row), similarly to mammary tumors 
(middle row) and DTC tumors (bottom row), metastasis 
tumors almost exclusively contained HER2+ cells. 
However, tumors formed by metastasis-derived cells 
showed a pattern of HIF-1α expression more similar to 
DTC-derived tumor than mammary, as shown in Figure 
5B. We next analysed by qPCR the levels of HIF-1α 
target genes whose expression was relatively high in DTC 
tumors, including VEGF and BNIP3, as well as miR-
210. We found that DTC tumors expressed significantly 
higher BNIP3 levels compared to both mammary and 
metastasis tumors (Figure 5C). However, metastasis 
tumors expressed higher mRNA level of VEGF compared 
to mammary and DTC tumors (Figure 5D). On the other 
hand, metastasis tumors did not significantly differ in miR-
210 levels compared to DTC tumors (Figure 5E). We also 
evaluated stabilization of HIF-1α in the cells recovered 
from metastasis tumors (Figure 5F-5G). We found that 
although metastasis tumor cell lines equally expressed 
HER2 compared to the mammary and DTC tumor cell 
lines (Figure 5F), they showed higher HIF-1α levels 
compared to DTC tumor cell line (Figure 5G, left panel). 
These findings suggest that metastasis tumors might have 
an exacerbated, hypoxic phenotype compared to DTC 
Figure 4: HIF-1α is required for DTC tumorigenicity. A. HIF-1α, VEGF and BNIP3 mRNA levels were measured by qPCR in 
DTC transduced with a lentiviral vector silencing HIF-1α (shHIF-1α) compared to control (shRNA). B. Tumor growth curves of control 
(shRNA, black dots) and HIF-1α (shHIF-1α, white dots) transduced DTC cells. Mean tumor volume (n=6 samples/group) ± SD was plotted 
as a function of time (days). C. Representative pictures of tumors at sacrifice of the mice (day 21). D. Representative haematoxylin and 
eosin-stained sections (H&E) of tumors. Pictures were acquired at 1.25x magnification, scale bar 10 mm. E. Analysis of HIF-1α, VEGF and 
BNIP3 mRNA levels in shRNA and shHIF-1α DTC tumors by qPCR. F. HIF-1α expression in early and late DTC by immunofluorescence 
analysis. On the left, representative confocal images of early (upper panels) and late (lower panels) DTC taken at 63x magnification, scale 
bar 20 μm. Nuclei were stained in blue, CK8-18 in red and HIF-1α in green. On the right, histogram reporting mean numbers of CK8-18+/
HIF-1α+ DTC per 2 x 106 BM cells. *P < 0.05.
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tumors. Furthermore, HIF-1α in these cells relocated, 
as expected, in the nuclei when placed under hypoxic 
conditions (Figure 5F, right panel). In conclusion, the 
HIF-1α signature detected in DTC tumors is substantially 
shared by tumors formed by metastatic cells found in the 
lung of BALB-neuT mice.
DISCUSSION
Many studies characterized DTC by analyzing 
lesions derived from the injection of established cell 
lines or primary tumor cells as a source of DTC [27, 
28]. In addition, most clinical studies reported a strong 
correlation between DTC presence and development of 
future metastases, even in patients with early stage tumors. 
However, only a limited number of studies directly 
addressed the tumorigenic capability of DTC or circulating 
tumor cells (CTC), and in all cases they utilized samples 
from patients with advanced cancers [29-31].
We were intrigued by the finding that early dormant 
DTC derived from the BALB-neuT transgenic mice could 
be reactivated to invade the BM by events following host 
irradiation [14]. This suggested that early DTC could be 
dependent on microenvironment cues to acquire tumorigenic 
properties, such as angiogenesis or inflammation. Therefore, 
the initial purpose of this study was to better characterize the 
tumorigenic behavior of early DTC in the context of pro-
angiogenic microenvironment.
Figure 5: DTC-tumor hypoxic profile is partly shared with BALB-neuT tumor metastasis. A. Schematic representation of 
mammary, DTC and metastasis tumor generation; the right panel shows the histopathological analysis of mammary, DTC or metastasis 
tumors. A representative of each tumor frozen section was stained with H&E and HER2. Light microscopy images were taken at a 
magnification 1.25x (scale bar 10 mm), 2.5x (scale bar 1 mm) and 20x (scale bar 100 μm). B. Immunohistochemical analysis of HIF-
1α expression in metastasis, mammary and DTC tumors. A representative tumor frozen section is shown, photographed at 20x and at 
40x magnification. C-D. qPCR analysis of mRNA levels of BNIP3 C. and VEGF D. in mammary, DTC and metastasis tumors. Data 
represent mean relative expression of mRNA compared to mammary tumor (± SD), expressed as fold change. E. qPCR analysis of miR-
210 expression in mammary, DTC and metastasis tumors. Data are expressed as mean values (± SD), relative to the level of miR-210 in 
mammary tumors. F. Flow cytometric analysis of HER2 expression in mammary, DTC and metastasis tumor cell lines. A representative plot 
of the percentages of HER2+ cells in the population of mammary, DTC and metastasis tumor cell lines is shown. G. Immunofluorescence 
analysis of HIF-1α localization in mammary, DTC and metastasis tumor cell lines in normoxic and hypoxic conditions. In green HIF-1α 
staining, in blue nuclei; scale bar 20 μm. *P < 0.05, **P < 0.01, ***P < 0.001.
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Whilst this study did not find early DTC to be 
tumorigenic, we found that about 44% of BM samples 
containing late DTC were tumorigenic (Table 1). We found 
DTC tumorigenicity to be independent from the number of 
injected DTC (Table 1) and on the tumor burden of the 
donor (Supplementary Table S1), whereas it correlated 
with the age of the DTC donor mice. Hypothetically, subtle 
genetic aberrations or epigenetic alterations might underlie 
the different tumorigenic capability, as gross chromosomal 
differences between DTC from different stages of tumor 
in the BALB-neuT mouse model were not detected in 
previous studies [14]. It is still unclear whether early DTC 
could evolve into late DTC or if late DTC originate from 
the dissemination of cells from later stages of primary 
tumors. In support of the latter idea, DTC obtained from 
patients with clinically detectable tumors were found to be 
highly malignant [32]. Moreover, so far only CTC derived 
from patients with advanced stage cancer have shown 
tumorigenic potential in immunodeficient mice [29-31].
With regard to the finding that only 44% of BM 
samples from late DTC donors were tumorigenic, it should 
be stressed that DTC, like primary tumor cells, have been 
described to be heterogeneous [9] and therefore it can be 
presumed that DTC do not have equivalent tumorigenic 
capabilities. Speculatively, it could well be that not all 
DTC in this mouse model express the activated Her2/
neu oncogene at all times, as DTC detection relies on the 
enumeration of CK8-18 positive cells [14]. Podsypanina et 
al. demonstrated that even untransformed epithelial cells 
can circulate and settle in a variety of organs for a long 
time, but only upon expression of the driver oncogene 
they begin to expand and establish metastatic growth 
[11]. Activation of oncogenes, such as Her2/neu, may 
be crucial to tip the balance between active growth and 
dormancy. Indeed, Her2/neu activation leads to AKT and 
ERK phosphorylation [13, 33, 34].
With regard to angiogenesis, our results indicate 
that the tumorigenic behavior of late DTC is substantially 
independent from exogenous angiogenic factors, such 
as bFGF. On the other hand, in line with the established 
role of angiogenesis as tumor promoter, exogenous 
bFGF accelerated the growth of secondary DTC tumors. 
Thus, late DTC appear to be fully equipped with the 
capability of inducing the angiogenic switch and results 
of transcriptome analysis lend support to this hypothesis. 
In fact, microarray data disclosed that DTC tumors have 
a deregulated hypoxia pathway and that this profile is 
maintained upon in vitro culture of these cells (Figure 2 
and 3). We found that DTC tumors and their ex vivo culture 
have elevated mRNA levels of BNIP3, a pro-survival 
gene involved in hypoxia-driven autophagy [22], and 
VEGF, a potent angiogenic factor [20] (Figure 2C-2D and 
Figure 3D-3E), as well as miR-210, a key microRNA that 
regulates angiogenesis and survival in response to hypoxia 
[26]. These findings might likely explain why late DTC 
outgrowth was not affected by the angiogenic factor bFGF 
(Supplementary Table S2) and also underscore reduced 
dependence of late DTC from the microenvironment, 
compared with early DTC. It could thus be that the lack 
of tumor formation by early DTC is due to an inadequate 
microenvironment in our experimental setting.
Another interesting observation of our study is 
that cells derived from DTC tumors maintain high basal 
levels of HIF-1α protein compared to the mammary tumor 
cell line (Figure 3A-3C). Some authors found that HIF-
1α stabilization is caused by HER2 overexpression [34]. 
However, we did not find increased HER2 expression in 
DTC tumors, compared with mammary tumors (Figure 
1A-1B), nor did we find significant differences in HIF-1α 
mRNA levels, implying post-transcriptional stabilization 
of HIF-1α by as yet unknown mechanisms.
The precise role of HIF-1α in DTC is unknown. 
Intriguingly, DTC have been described to have predilection 
for the hematopoietic stem cell niches, a predominantly 
hypoxic environment [35, 36]. Speculatively, activation 
of HIF-1α could be critical for DTC to survive in these 
bone marrow niches or, alternatively, oxygen-independent 
upregulation of HIF-1α could arise from upregulation 
of upstream signaling pathways involved in tumor 
progression. In any case, attenuation of HIF-1α expression 
was able to reduce tumorigenic capabilities of DTC cells 
(Figure 4), thus underscoring its contribution to tumor 
formation. In line with our findings, in the MMTV-PyMT 
murine model, HIF-1α was shown to be necessary for 
acceleration of tumor onset and progression [37-40].
Along this line, we also report that metastasis 
tumors partly shared the hypoxic profile of DTC tumors 
(Figure 5B-5G). Metastasis tumors did not significantly 
differ in miR-210 expression compared to DTC tumors 
(Figure 5E), but had more pronounced VEGF expression 
(Figure 5D). On the other hand, DTC tumors appeared 
to have elevated BNIP3, compared to the metastasis 
tumors (Figure 5C). Hypoxia not only promotes cancer 
dissemination and stemness, but it has also been described 
to promote metastasis from bone to lung [37, 41, 42], 
raising the hypothesis that lung metastasis could stem 
from BM-derived DTC.
Besides a hypoxic profile, DTC tumors also have 
marked expression of cancer relevant genes (Table 3) 
such as the metastasis-promoting tetraspanin 8 (TSPAN8) 
[43], proliferation and migration promoting epidermal 
growth factor substrate 8 (EPS8) [44, 45]. These results 
suggest that the DTC tumor phenotype could endow 
them with enhanced aggressiveness; indeed, it would 
be interesting to examine whether this phenotype might 
constitute a prerequisite for metastasis formation in this 
mouse model. Thus, our findings also suggest the alluring 
possibility that late DTC could be enriched in metastasis 
precursors/metastasis-initiating cells. In future studies, 
it will be important to refine methods of isolation and 
characterization of late DTC from the BM, whose number 
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is extremely low, to validate the signature obtained from 
DTC-derived tumors.
In conclusion, our observations connect tumorigenic 
features of DTC with a hypoxic signature and prompt 
further investigation in DTC or CTC from patients.
MATERIALS AND METHODS
Transgenic mice
Founder BALB-neuT male mice were kindly 
provided by Dr. Guido Forni (Torino, Italy) [55]. BALB-
neuT mice were bred with in house BALB/c female mice. 
Female offspring were then screened for the presence of 
Her2/neu oncogene as previously described [55]. NOD/
SCID-γ-/- (NSG) mice were purchased from Charles River 
and bred in house. Procedures involving animals and their 
care were performed according to institutional guidelines 
that comply with national and international laws and 
policies (EEC Council Directive 86/609, OJ L358, 12 
December 1987), and this study was approved by the 
Institutional Ethics Committee for Animal Studies.
Cell culture conditions
TUBO cells derived from BALB-neuT mammary 
cancer cells [46] were maintained in DMEM with 1% 
Penicillin-Streptomycin (Lonza, Basel, Switzerland), 1% 
L-Glutamine (Invitrogen, Monza, Italy) and 20% Fetal 
Calf Serum (FCS, Gibco, Invitrogen), unless otherwise 
stated. BM cells were harvested by flushing the femurs 
and tibiae with cold PBS and filtering through 100 μm 
cell strainers. Red blood cells were lysed by NH4Cl/
KHCO3/EDTA buffer; cells were then re-suspended in 
PBS and viability assessed by trypan blue dye (Invitrogen) 
exclusion. For hypoxia experiments, cells were seeded at 
5 x 105 cell/well and maintained in either normoxia or 
hypoxia (0.5 % O2) for 24 hours in an InVivo2 300 hypoxic 
chamber (Ruskinn Technology, Mid Glamorgan, U.K.). In 
order to attenuate HIF-1α expression, 3x105 DTC cells 
were plated and infected overnight with a pLKO1-puro 
lentivirus encoding an HIF-1α-specific shRNA. Control 
cells were infected with a vector encoding a shRNA of 
irrelevant sequence. The following shRNA sequence was 
used to target HIF-1α:
CCGGTGCTCTTTGTGGTTGGATCTACTCGAG
TAGATCCAACCACAAAGAGCATTTTT
Lentiviral plasmids were purchased from Sigma-
Aldrich (St. Louis, MO, USA) and the vector was 
produced as previously described [47].
Immunofluorescence analysis
To evaluate DTC numbers, BM cells were 
resuspended in PBS and placed on positively charged 
slides to air dry. Dried spots of cells were fixed and 
permeabilized for 15 min with ice-cold methanol at 
-20°C and then processed for staining. Anti-HER2/ErbB2 
(29D8) rabbit monoclonal antibody (Cell Signaling, 
Boston, MD, USA) was used at 1:400 dilution overnight 
at 4°C. Guinea-pig anti-Cytokeratin (CK) 8-18 (Progen, 
Heidelberg, Germany) was used at 1:100 for one hour at 
room temperature. Anti-HIF-1α rabbit antibody (NB100-
479) was purchased from Novus Biologicals (Littleton, 
CO, USA) and used at 1:100 dilution overnight at 4°C. 
Alexa Fluorescent secondary antibodies were purchased 
from Molecular Probes (Invitrogen). Cell nuclei were 
visualized with TO-PRO-3 (Invitrogen). All images were 
taken with Zeiss LSM510 (Oberkochen, Germany) and 
Leica LM5 (Wetzlar, Germany) confocal microscope at 
the specified magnification. TUBO cells cultured under 
normoxic or hypoxic conditions (0.5% pO2 for 24 h) were 
used as positive control for HER2 and HIF-1α staining, 
respectively.
Immunohistochemical analysis
For immunohistochemical analysis of HER2 
expression, tumors were fixed in formalin and included 
in paraffin. Tumor sections were then de-paraffinized 
and rehydrated before antigen retrieval in EDTA buffer 
(pH 8.0). For analysis of HER2 expression on frozen 
tumor sections, these were fixed in 4% formaldehyde 
for 10 min. To analyze the expression of HIF-1α, frozen 
sections were obtained and fixed in ice-cold methanol for 
15 min. Endogenous peroxidases were blocked with 3% 
hydrogen peroxidase treatment for 30 min. To prevent 
non-specific antigen binding, sections were incubated 
with 5% normal goat serum 60 min prior to staining 
with HER2/ErbB2 antibody (1:400; Cell Signaling) or 
with anti-HIF-1α (Novus Biologicals) 1:200 overnight. 
The slides were then incubated with the biotinylated 
secondary antibody, followed by incubation in an avidin-
biotinylated peroxidase complex reagent (Vectastain 
Rabbit ABC Elite kit; Vector Laboratories, Burlingame, 
CA, USA), and visualized with diaminobenzidine tetra-
hydrochloride (DAB; Sigma-Aldrich) treatment. The 
slides were counterstained with Mayer’s haematoxylin, 
dehydrated, and finally mounted with Entellan (BDH 
Ltd, Poole, Canada). For HER2 staining, tumor sections 
from BALB-neuT tumors served as positive control. For 
HIF-1α staining, sections of hypoxic tumor xenografts 
analysed in previous studies [48] were used as positive 
control. Quantification of the percentage of HIF-1α 
positive nuclei was performed on regions of interest 
containing approximately 20,000 nuclei, and analysed with 
Visiopharm software (Horsholm, Denmark).
Flow cytometry (FACS) analysis
For HER2 staining, cells were fixed with 4% 
paraformaldehyde and incubated overnight in methanol. 
The cells were thereafter incubated with 1% BSA to 
prevent non-specific binding and with anti-HER2/Erb2 
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(1:400) antibody followed by the appropriate secondary 
antibody (Alexa 1:500; Invitrogen) [49]. The samples 
were analysed with FACS LSRII (BD Bioscience, Franklin 
Lakes, NJ, USA); data were collected from at least 1 x 
105 cells/sample and elaborated with FlowJo software 
(TreeStar, Ashland, OR, USA).
In vivo studies
For subcutaneous (s.c.) injection, 10 x 106 BM cells 
or 1 x 105 tumor cells were re-suspended in a total of 
200 μl PBS with 1 μg murine bFGF (Peprotech, Rocky 
Hill, NJ, USA) mixed with 400 μl of Matrigel (Becton-
Dickinson), according to a previously published protocol 
[18]. We injected a total of 300 μl (cells plus Matrigel mix) 
per dorsolateral flank. Tumors were inspected weekly and 
measured with caliper. Tumor volumes were calculated 
according to the following formula: Tumor volume (mm3) 
= L (longest diameter) x l (shortest diameter)2 x 0.5 [50]. 
Tumor growth was scored when tumor volumes exceeded 
10 mm3.
For the Matrigel assay, a total of 5 x 106 of BM 
cells in 400 μl of Matrigel supplemented with bFGF and/
or VEGF were s.c. injected as previously described [18]. 
After one week Matrigel plugs were recovered, snap 
frozen in liquid nitrogen and stored at -80°C.
For in vivo silencing experiments, DTC cells 
transduced with lentiviral vectors where s.c injected 
(2.5x105/flank) in 200 μl of Matrigel in NSG mice.
Microarray
MoGene 2.0 ST array (Affymetrics, Santa Clara, 
CA, USA) was used according to manufacturer’s 
instruction using the recommended amount of RNA 
(100 ηg). Briefly, tumor masses from primary BALB-
neuT mammary tumors and DTC tumors grown in 
NSG mice were snap-frozen at harvest. Cryostat 
shavings were used to extract RNA and a representative 
section was kept for Haematoxylin and Eosin (H&E) 
staining in order to evaluate tumor tissue anatomy and 
to quantify necrotic areas. The quality and quantity of 
total RNA from samples was determined using Agilent 
2100 Bioanalyzer and Nanodrop spectrophotometer. 
Hybridization, washing, staining and scanner procedures 
were done using a Genechip Affymetrix station (Fluidics 
station 450, GeneChip Scanner 3000) as recommended 
by manufacturer. Laser scanning generated digitalized 
image data and CEL files that were used for the 
subsequent statistical analysis. The data were loaded in 
oneChannelGUI [51], normalized using sketch-quantile 
normalization and filtered by IQR > 0.25 to remove 
unchanged transcripts. To assess differential expression, 
we used an empirical Bayesian method [52] together 
with a false discovery rate (FDR) correction of the 
P-value. Genes were selected as differentially expressed 
if characterized by a FDR ≤ 0.05 and an absolute log2 fold 
change ≥ 1. The microarray data have been deposited in 
the GEO database under accession number GSE71251.
Micro RNA assay
A total of 10 ng of RNA was retro-transcribed 
with Custom TaqMan Small RNA Assay, using TaqMan 
MicroRNA Assay primers for miR-210 and snoRNA-202 
(all from Applied Biosystems, Foster City, CA, USA) 
according to manufacturer’s recommendation. qPCR 
was performed on 1 ng of retro-transcribed product using 
TaqMan MicroRNA Assay primers for miR-210 and 
snoRNA-202 (Applied Biosystems), and the data were 
normalized to snoRNA-202.
RNA extraction, reverse transcription and gene 
expression analysis
Total RNA was extracted from cell populations 
by the TRIzol method according to the manufacturer's 
instructions. cDNA was synthesized from 0.5-2 μg of total 
RNA using the reverse transcriptase (High Capacity cDNA 
Reverse Transcription Kit, Applied Biosystems). Each 
sample was run in triplicate on ABI PRISMR 7900HT 
Sequence Detection System (PE Biosystems, Foster City, 
CA, USA). Results were analyzed with BNIP3 [22] and 
VEGF primer [53] using the comparative ΔΔCt method 
normalized to the housekeeping gene GAPDH. qPCR 
efficiency was in the range 95-105%.
Western blot analysis
Cells were lysed in a buffer containing 140 mM 
NaCl, 20 mM Tris-HCl pH 7.4, 5 mM EDTA, 10% 
glycerol, 1% Triton X-100. Forty μg of cell lysate were 
loaded and subjected to SDS-PAGE and Western blotting 
(WB). The membranes were hybridized overnight with 
rabbit anti-mouse actin (1:5,000; Sigma-Aldrich) and 
rabbit anti-mouse HIF-1α (1:1,000; Novus Biologicals), 
followed by incubation with anti-rabbit HRP-conjugated 
antibody (1:5,000 dilution, Amersham-Pharmacia, 
Little Chalfont, U.K.). The signal was finally detected 
by chemiluminescence with SuperSignal kit (Pierce, 
Rockford, IL, USA) and lane densitometry analyzed by 
standard procedures [49].
Statistical analysis
Data were analyzed using SigmaPlot software. 
Student’s t-test, 2-way ANOVA statistical test were used as 
indicated. P values ≤ 0.05 were considered as significant.
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